BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Andoh A, Ogawa A, Kitamura K, Inatomi O, Fujino S, Tsujikawa T, Sasaki M, Mitsuyama K, Fujiyama Y. Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol. 2004;39:1150-1157. [PMID: 15622478 DOI: 10.1007/s00535-004-1464-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Shimada M, Iwase H, Tsuzuki T, Hirashima N, Kobayashi K, Hibino Y, Watanabe H, Ryuge N, Ando T, Goto H. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis. Ther Apher Dial. 2008;12:368-373. [PMID: 18937719 DOI: 10.1111/j.1744-9987.2008.00611.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
2 Akatsu T, Shimazu M, Shinoda M, Kawachi S, Tanabe M, Aiura K, Ueda M, Kameyama K, Sakamoto M, Kitajima M, Kitagawa Y. Intrahepatic Cholangiocarcinoma with Old Infestation of Schistosoma japonicum: Report of a Case. Surg Today 2007;37:905-9. [DOI: 10.1007/s00595-007-3485-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Mitsuyama K, Sata M. Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action. Cytotherapy. 2009;11:229-237. [PMID: 19241197 DOI: 10.1080/14653240902725566] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
4 Hanai H, Iida T, Ikeya K, Abe J, Maruyama Y, Shimura T, Sugimoto K, Watanabe F. A new paradigm in ulcerative colitis: regulatory T cells are key factor which induces/exacerbates UC through an immune imbalance. Mol Immunol. 2013;54:173-180. [PMID: 23280396 DOI: 10.1016/j.molimm.2012.11.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
5 Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, Lam SK, Xiao SD. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006;21:1772-82. [PMID: 17074013 DOI: 10.1111/j.1440-1746.2006.04674.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
6 Sakata Y, Iwakiri R, Amemori S, Yamaguchi K, Fujise T, Otani H, Shimoda R, Tsunada S, Sakata H, Ikeda Y, Ando T, Nakafusa Y, Fujimoto K. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. Eur J Gastroenterol Hepatol 2008;20:629-33. [PMID: 18679064 DOI: 10.1097/MEG.0b013e3282f5e9a4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
7 Matsuda M, Fujii H. Chronic Schistosomiasis Japonica is an Independent Adverse Prognostic Factor for Survival in Hepatocellular Carcinoma Patients Who Have Undergone Hepatic Resection: Clinicopathological and Prognostic Analysis of 198 Consecutive Patients. World J Surg 2009;33:2644-50. [DOI: 10.1007/s00268-009-0228-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 Zhang H, Zhang Z, Song G, Tang X, Song H, Deng A, Wang W, Wu L, Qin H. Development of an XBP1 agonist, HLJ2, as a potential therapeutic agent for ulcerative colitis. Eur J Pharm Sci 2017;109:56-64. [PMID: 28757346 DOI: 10.1016/j.ejps.2017.07.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Matsumoto T, Andoh A, Okawa K, Ito H, Torii A, Yoshikawa S, Nakaoka R, Okuyama Y, Oshitani N, Nishishita M, Watanabe K, Fukunaga K, Ohnishi K, Kusaka T, Yokoyama Y, Sasaki M, Tsujikawa T, Aoki T, Kusaka T, Takeda Y, Umehara Y, Nakamura S, Fujiyama Y. Multivariate Analysis for Factors Predicting Rapid Response of Leukocytapheresis in Patients With Steroid-resistant Ulcerative Colitis: A Multicenter Prospective Open-label Study. Therapeutic Apheresis and Dialysis 2008;12:484-90. [DOI: 10.1111/j.1744-9987.2008.00639.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
10 Sawada K, Ohdo M, Ino T, Nakamura T, Numata T, Shibata H, Sakou J, Kusada M, Hibi T. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study. Ther Apher Dial. 2016;20:197-204. [PMID: 26771066 DOI: 10.1111/1744-9987.12357] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ohkawara T, Saito M, Nakagawa S, Ohizumi H, Tamaki T, Yonekawa M, Takeda H, Asaka M, Nishihira J, Kawamura A. A Case Report of the Therapeutic Effect of Cryofiltration in a Patient With Glucocorticoid-Resistant Ulcerative Colitis. Therapher Dial 2007;11:159-62. [DOI: 10.1111/j.1744-9987.2007.00418.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
12 Andoh A, Tsujikawa T, Inatomi O, Deguchi Y, Sasaki M, Obata H, Mitsuyama K, Fujiyama Y. Leukocytapheresis Therapy Modulates Circulating T cell Subsets in Patients With Ulcerative Colitis. Therapher Dial 2005;9:270-6. [DOI: 10.1111/j.1774-9987.2005.00270.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
13 Takemoto K, Kuriyama M, Kato J, Suzuki H, Ishikawa S, Hiraoka S, Yamamoto K. Ratio of Platelet Reduction is an Early Predictive Factor for the Effectiveness of Leukocytapheresis for Ulcerative Colitis Patients. Therapeutic Apheresis and Dialysis 2009;13:6-13. [DOI: 10.1111/j.1744-9987.2009.00649.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Okada AA. Behçet's disease: general concepts and recent advances. Curr Opin Ophthalmol 2006;17:551-6. [PMID: 17065924 DOI: 10.1097/01.icu.0000247411.59213.bb] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
15 Yagi Y, Andoh A, Inatomi O, Bamba S, Tsujikawa T, Fujiyama Y, Mitsuyama K, Yoshida T. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol. 2006;41:540-546. [PMID: 16868801 DOI: 10.1007/s00535-006-1797-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
16 Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007;102:2058-2069. [PMID: 17561966 DOI: 10.1111/j.1572-0241.2007.01343.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 143] [Article Influence: 10.5] [Reference Citation Analysis]
17 Zheng XY, Lv YF, Li S, Li Q, Zhang QN, Zhang XT, Hao ZM. Recombinant adeno-associated virus carrying thymosin β4 suppresses experimental colitis in mice. World J Gastroenterol 2017;23:242-55. [PMID: 28127198 DOI: 10.3748/wjg.v23.i2.242] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
18 Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion 2008;77:96-107. [PMID: 18382085 DOI: 10.1159/000122473] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
19 Itoh Y, Takeshita Y, Ozawa Y, Tohma S, Umemura S. A Case Report of Leukocytapheresis for Refractory Leg Ulcers Complicated With Rheumatoid Arthritis. Therapher Dial 2006;10:419-24. [DOI: 10.1111/j.1744-9987.2006.00405.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Tomomasa T, Tajiri H, Kagimoto S, Shimizu T, Yoden A, Ushijima K, Uchida K, Kaneko H, Abukawa D, Konno M, Maisawa S, Kohsaka T, Kobayashi A; Japanese Study Group for Pediatric Ulcerative Colitis. Leukocytapheresis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr 2011;53:34-9. [PMID: 21694533 DOI: 10.1097/MPG.0b013e31821058bc] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
21 Araki Y, Mitsuyama K, Nagae T, Tou Y, Nakagawa M, Iwatani Y, Harada M, Ozasa H, Sata M, Noake T. Leukocytapheresis for the treatment of active pouchitis: a pilot study. J Gastroenterol 2008;43:571-5. [PMID: 18648745 DOI: 10.1007/s00535-008-2199-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
22 Chen D. Recent advances in the treatment of adult-onset Still's disease. Expert Opinion on Orphan Drugs 2013;1:103-13. [DOI: 10.1517/21678707.2013.754725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Miyamoto H, Okahisa T, Iwaki H, Murata M, Ito S, Nitta Y, Akutagawa M, Kinouchi Y, Ohnishi Y, Oto J, Nishimura M. Influence of Leukocytapheresis Therapy for Ulcerative Colitis on Anemia and Hemodynamics. Therapher Dial 2007;11:16-21. [DOI: 10.1111/j.1744-9987.2007.00451.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Sáez-gonzález E, Moret I, Alvarez-sotomayor D, Díaz-jaime FC, Cerrillo E, Iborra M, Nos P, Beltrán B. Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease. Dig Dis Sci 2017;62:1417-25. [DOI: 10.1007/s10620-017-4577-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
25 Costa SK, Starr A, Hyslop S, Gilmore D, Brain SD. How important are NK1 receptors for influencing microvascular inflammation and itch in the skin? Studies using Phoneutria nigriventer venom. Vascul Pharmacol 2006;45:209-14. [PMID: 16914387 DOI: 10.1016/j.vph.2005.08.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
26 Muratov V, Lundahl J, Mandic-havelka A, Elvin K, Öst Å, Shizume Y, Furuya K, Löfberg R. Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study. J Clin Apheresis 2010;25:287-93. [DOI: 10.1002/jca.20255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
27 Kanke K, Hoshino M, Tominaga K, Nakano M, Terano A, Hiraishi H. Selection of Anticoagulants for Leukocytapheresis Therapy in Cases of Active Ulcerative Colitis. Blood Purif 2007;25:370-6. [DOI: 10.1159/000107712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
28 Ramlow W, Waitz G, Sparmann G, Prophet H, Bodammer P, Emmrich J. First Human Application of a Novel Adsorptive-Type Cytapheresis Module in Patients With Active Ulcerative Colitis: A Pilot Study: Novel Apheresis Device for UC. Therapeutic Apheresis and Dialysis 2013;17:339-47. [DOI: 10.1111/1744-9987.12007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
29 Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment Pharmacol Ther Symp Series 2006;2:147-52. [DOI: 10.1111/j.1746-6342.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Andoh A, Bamba S, Brittan M, Fujiyama Y, Wright NA. Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacol Ther. 2007;114:94-106. [PMID: 17328956 DOI: 10.1016/j.pharmthera.2006.12.004] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 6.6] [Reference Citation Analysis]
31 Yagi Y, Andoh A, Ogawa A, Bamba S, Tsujikawa T, Sasaki M, Mitsuyama K, Fujiyama Y. Microarray analysis of leukocytapheresis-induced changes in gene expression patterns of peripheral blood mononuclear cells in patients with ulcerative colitis. Ther Apher Dial. 2007;11:331-336. [PMID: 17845392 DOI: 10.1111/j.1744-9987.2007.00495.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
33 Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis: EFFICACY AND ENDOSCOPIC PREDICTION OF CYTAPHERESIS THERAPY IN UC. Alimentary Pharmacology & Therapeutics 2006;24:147-52. [DOI: 10.1111/j.1365-2036.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]